News

RDIF and ChemRar present Avifavir to Latin American representatives

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar GrRDIF and ChemRar present Avifavir to Latin American representativesoup, supported by the Russian Embassy in Guatemala held a video conference on July 10, 2020 with representatives of Latin American and Caribbean states to present the first Russian anti-COVID drug Avifavir, the RDIF’s corporate website reports.

The regions are now facing an outbreak of coronavirus infection and all effective tools to combat coronavirus are in demand from the government agencies and medical institutions in those countries.

Almost 1,500 representatives from Latin American and Caribbean states , H.E. President of the Central American Parliament Nadia De León Torres, members of Pan-American Medical Association, Latin American Parliament participated in the conference.

The conference was arranged in partnership with Bering-Bellingshausen Institute for the Americas – a non-profit organization promoting dialogue of politicians, businessmen, journalists, scientists from Russia and the CIS countries with colleagues from the Americas.

Representatives from RDIF and ChemRar Group provided conference participants with information for using Avifavir in coronavirus therapy and its advantages compared to other drugs currently in use around the world to combat the pandemic. Following the conference agreements were reached to continue dialogues with representatives of Latin American states around the supply of Avifavir.

Avifavir is the first clinically proven and registered drug in Russia against coronavirus. It is also the first Favipiravir-based drug in the world approved for treatment of COVID-19. On May 29, 2020, Avifavir received a registration certificate from Russia’s Ministry of Health and on June 3, 2020, the Ministry of Health included Avifavir in the latest seventh edition of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19. Avifavir has proven effective in clinical trials, disrupting the reproduction mechanisms of coronavirus.

Avifavir delivers best results when used at the early and middle stages of infection. As a result, RDIF has asked to the Ministry of Health of the Russian Federation to allow the use of Avifavir by outpatients who receive therapy at home.

Previous ArticleNext Article